Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM2017FIT: VMP-Rd vs KRd +/- Daratumumab in Elderly Fit NDMM
NCT03742297Phase 3Active, not recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Oct 2018
- Primary completion
- Jul 2023
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of carfilzomib, daratumumab in multiple myeloma (MM), sponsored by Fundación PETHEMA. Started Oct 2018; status: active, not recruiting.
02
Drugs
carfilzomibdaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03742297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742297.